Our data from March and April 2026 shows some of those trends have continued, but federal regulators are beginning to enforce fraud more effectively
The relative risk of symptomatic cholelithiasis was 1.6, 0.9, and 1.4 in liraglutide, dulaglutide, and semaglutide with number needed to harm of 3.14, 16.67, and 5.56, respectively
At the same time, a 2026 Aon analysis found that sustained GLP1 use for employees with Type 2 diabetes was associated with 6% lower medical cost growth after 30 months, highlighting both the budget impact and the potential longterm savings
Sawicki et al., 2015
Register now for "Breaking the Status Quo," a virtual summit about PBM reform hosted by Pharmacists United for Truth and Transparency Wednesday, September 24 at 10:00 am EDT International News Reports of fentanyl pills in Costa Rica and fake pharmacies in the Dominican Republic